built a radiogenomic classifier based on patients with IDH-WT GBM certified by next-generation sequencing (NGS), which noninvasively predicts retinoblastoma 1, p53, and Receptor tyrosine kinase (RTK) core signaling pathways (31). The gene discussed is IDH2; the disease is glioblastoma.